Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It has been yet another quiet day, with no indication of the expected half-year report, and a low volume of insignificant trades. This can be the case with some companies during the summer months. Perhaps we will receive some news regarding current developments when the latest report is issued, probably in September?
Last calling for 6p offer!
Address is iq-ai@imagingbiometrics.com
Drop him an e-mail.
I did last year and he replied by return, not got his e-mial address to hand at moment
Thanks TLW but it was question for Mr TB who frequents this BB.
It was issued on September 19 in 2019.
I can find no reference as to when the company intends to release this year's Half Year Report.
We had it on the 7th of August last year…………
Hi MR TB any chance of releasing this anytime soon.
To come back to Brian re competition for Gad - I think IB are perfectly positioned to capitalise on a contrast free product. Firstly, 40% of MRI scans using an agent are neuro - IB already lead the way in Neuro imaging with their DSC approach which was acknowledged as the standard in DSC imaging in June 2020. The subsequent sales to Keck, Montgomery & LA County are validation of this (as well the the numerous clinical trials their tech is requested for as recognised by the US National Comprehensive Cancer Network & NCI).
There is only 1 other GAD free offering with many other research groups trying to develop a 0% but falling short. The results from the potential competitors have fallen short on the quality of their imaging & all still require some contrast agent (in some cases 10% - but this still means it has to be administered).
The huge competitive edge IB have are: 1. they will be contrast agent FREE 2. the quality of their imaging - so far no-one has been able to replicate the results of a contrast image to the standard of IB (this was the TB's 'wow' comment & results have been published) 3. IB has been patented (huge advantage).
Having read your contributions to this board
I find it difficult to believe anyone would bother to read your post.
let alone take any note of them. Back to school soon for you no doubt!
Fine brainspark. No one is asking you not to contribute. You are entitled to your opinion, although I disagree with you.
My polite request was that if you are encouraging short-term selling of this company’s stock, could you please start a new thread. This will mean that we do not lose valuable information if your post is deleted and the entire thread with it.
May 19th 2021 was your chance to hold the company to account, what you seem to struggle with is the fact that many people are underwater here
Rather than attacking holders here get on the phone and speak with company direct or email your feelings
Unfortuately these boards are too easily trolled by derampers and shorters as well as the rampers
i assume you no longer hold here?
Who is ramping?…………….Deluded
This is one of the quietest BB on LSE : )
No I will not leave this bb for only rampers who cost people hard earned money.
This company has not delivered and will be held to account.
Again no news, no buys....going one way and that is south
brainspark. If you must insist on bringing your short term selling agenda to this board, could you at least start a new thread please? Your brand of posting will inevitably be deleted, and with it comments with useful information from other contributors.
GAD free....Google how many other companies are doing it. You have been sold a Turkey.
No buys...only sells. little cash left. Easy shorting money
Agreed - the SP currently has no relation to on-going operations.
In terms of buyout - I think the Gad free product and GaM trial will be watched closely & certainly attract interest from global players who could generate huge revenue's from a successful product on either score. Maybe products will be carved out for sale or someone may want to take IB lock stock.
I think news of GaM will be September & Gad FDA application could be anytime. I anticipate an update prior to trial start (broker appointment) but we will see how it plays out.
For now, it is a step at a time but the near future is looking extremely exciting.
The current trading volume is small and of little consequence. “readicant” has given a very clear indication of the potential of this company and its products.
Earlier statements suggest that we might hear something in September. It will be interesting to see how the market reacts. I am more interested in long term value, although it is possible that the company might be bought up.
The only sellers today was you LOL
The selling to pay bills has stopped.
Another few weeks of quiet and then............
Thank you for sharing readicant. As always, you have brought useful information, and your well-informed opinion to this board. I concur with your view as to the future potential of this company. Like you, I have no problem with holding until developments unfold.
IMO - IQAI are already showing signs they are readying themselves to becoming a much bigger player (in tandem with the position of their existing products and developments - IB Neuro, SC, IB Trax, GaM, Gad, IB CAD etc) with them choosing to not RNS all news & having a quieter presence on media platforms.
The next big indicator of this would be an appointment of a broker - which, to me, would show an ambition to attract larger investors, which implies an anticipation of mcap increase.
It is an easy hold for me - DYOR & each to their own strategy.
Ignoring all other existing products and developments, consider the potential global market for Gad free - IB are on the brink of applying for FDA clearance for their, now US patented, Gad (contrast) free imaging tech. The material cost of Gad is in the region of $1.3 billion per year in US alone without going into the costs of time and resource to administer the agents & associated harm to health that could bring potential litigation. If they crack this product it will transform the company.
They delivered a patent on the imaging equipment.
That now sits in the office cupboard with stonechecker, apparently unwanted!
No deal news for months??? Have they got enough cash ? Where are the half year results.
From all the 'wow' comments by the chairman they have delivered nothing this year
Thank you for providing the link Nolupus. It made interesting viewing. Trevor Brown is still very much on top of his game. He is presumably looking to retire, although he will remain as CEO of BRH to see throughthe development of their current project. He is also IQAI's CEO, and major shareholder, and he will surely be considering selling his majority shareholding here at a substantial profit? Would it be feasible for him to sell all his shareholding to an interested party, who would then be close to a position where they could launch a buyout?
The IP within this company is substantive and has attracted favourable attention from professionals within the field. It is at the cutting edge of medical diagnostics. I concur with the opinions expressed by fellow contributors, whose understanding of this technology, and its applications, exceeds my own. This company is in a good place for a takeover by a larger party. The only issue that remains for me is the magnitude of any potential offer? I have arbitrarily assigned a value of 15 - 20p per share, based on transient highs achieved during the last year. I do not have the expertise to fully evaluate the true worth of this technology.
On BRH but gives credence to Trek’s viewpoint about TB’s intentions , imo
https://www.proactiveinvestors.co.uk/companies/news/957757/braveheart-investment-group-s-trevor-brown-on-recent-raise-and-covid-19-test-development-plans-957757.html